Table S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK

Autor: John M. Mariadason, Niall C. Tebbutt, Nick Pavlakis, Andrew J. Weickhardt, Matthias Ernst, Sarah A. Hayes, Alex Boussioutas, Katrin Sjoquist, Michael Buchert, Fiona Chionh, Kael L. Schoffer, David S. Williams, Andrew Martin, Laura J. Jenkins, Ian Y. Luk, David K. Lau

Supplementary Table 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e44cd024ad178f6598e7b1b1d326c3
https://doi.org/10.1158/1535-7163.22522705.v1

Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study

Autor: Michael Leonard, Friedlander, Martin, Stockler, Rachel, O'Connell, Merryn, Voysey, Amit, Oza, Kim, Gillies, Heidi, Donovan, Julie, Martyn, Katrin, Sjoquist, Phyllis, Butow, Madeleine T, King

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 24(5)

The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation. Patients' experience of symptoms is not well documented, and the impact of treatment on symptoms has not been evaluated in clinical trials. We report symptom bu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8229466cfb16821c9c6a0eed2270633f
https://pubmed.ncbi.nlm.nih.gov/24844219

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Autor: Lam, Lyn Ley¹ (AUTHOR) integrateii.study@sydney.edu.au, Pavlakis, Nick² (AUTHOR), Shitara, Kohei³ (AUTHOR), Sjoquist, Katrin M.¹ (AUTHOR), Martin, Andrew J.¹ (AUTHOR), Yip, Sonia¹ (AUTHOR), Kang, Yoon-Koo⁴ (AUTHOR), Bang, Yung-Jue⁵ (AUTHOR), Chen, Li-Tzong⁶ (AUTHOR), Moehler, Markus⁷ (AUTHOR), Bekaii-Saab, Tanios⁸ (AUTHOR), Alcindor, Thierry⁹ (AUTHOR), O'Callaghan, Christopher J.¹⁰ (AUTHOR), Tebbutt, Niall C.¹⁰ (AUTHOR), Hague, Wendy¹ (AUTHOR), Chan, Howard¹¹ (AUTHOR), Rha, Sun Young¹² (AUTHOR), Lee, Keun-Wook^5,13 (AUTHOR), Gebski, Val¹ (AUTHOR), Jaworski, Anthony¹ (AUTHOR)

Publikováno v: BMC Cancer. 2/22/2023, Vol. 23 Issue 1, p1-12. 12p.

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

Autor: Siu, Ho Wai Derrick^1,2 (AUTHOR) monarcc@ctc.usyd.edu.au, Tebbutt, Niall³ (AUTHOR), Chantrill, Lorraine⁴ (AUTHOR), Karapetis, Chris⁵ (AUTHOR), Steer, Christopher⁶ (AUTHOR), Wilson, Kate¹ (AUTHOR), Espinoza, David¹ (AUTHOR), Bailey, Lisa¹ (AUTHOR), Yip, Sonia¹ (AUTHOR), Cuff, Jeff⁷ (AUTHOR), Pavlakis, Nick⁸ (AUTHOR), Thavaneswaran, Subotheni⁹ (AUTHOR), Briscoe, Karen¹⁰ (AUTHOR), Srivastav, Ratnesh¹¹ (AUTHOR), Shannon, Jennifer¹² (AUTHOR), Segelov, Eva¹³ (AUTHOR), Tie, Jeannie¹⁴ (AUTHOR), Caird, Susan¹⁵ (AUTHOR), Francesconi, Alessandra¹⁶ (AUTHOR), Price, Timothy¹⁷ (AUTHOR)

Publikováno v: BMC Cancer. 8/18/2021, Vol. 21 Issue 1, p1-9. 9p.

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer.

Autor: Sjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R., Simes, R. John

Publikováno v: Journal of Cancer Research & Clinical Oncology; Jul2023, Vol. 149 Issue 8, p4959-4965, 7p